EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data

Bianca Kruger iD, Delva Shamley iD, Nyarai Desiree Soko iD, Collet Dandara iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13761 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Bianca Kruger und 3 weiteren Autor:innen. Beteiligte Einrichtung: Platform for Pharmacogenomics Research and Translation (PREMED), South African Medical Research Council, Cape Town, South Africa. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Cape Town, South African Medical Research Council (SAMRC), Council for Scientific and Industrial Research (CSIR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tamoxifen, a selective estrogen receptor modulator, is used to treat hormone receptor‐positive breast cancer. Tamoxifen acts as a prodrug, with its primary therapeutic effect mediated by its principal metabolite, endoxifen. However, tamoxifen has complex pharmacokinetics involving several drug‐metabolizing enzymes and transporters influencing its disposition. Genes encoding enzymes involved in tamoxifen disposition exhibit genetic polymorphisms which vary widely across world populations. This review highlights the lack of data on tamoxifen pharmacogenetics among African populations. Gaps in data are described in this study with the purpose that future research can address this dearth of research on the pharmacogenetics of tamoxifen among African breast cancer patients. Initiatives such as the African Pharmacogenomics Network (APN) are crucial in promoting comprehensive pharmacogenetics studies to pinpoint important variants in pharmacogenes that could be used to reduce toxicity and improve efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemalePharmacogeneticsCytochrome P-450 CYP2D6TamoxifenPolymorphism, Genetic

Substanzen

Cytochrome P-450 CYP2D6Tamoxifen

Autor:innen und Institutionen

  • Platform for Pharmacogenomics Research and Translation (PREMED), South African Medical Research Council, Cape Town, South Africa.
  • Pharmacogenomics and Drug Metabolism Research Group, Division of Human Genetics, Department of Pathology and Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town,…
  • Division of Clinical Anatomy and Biological Anthropology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Department of Pharmaceutical Technology, School of Allied Health Sciences, Harare Institute of Technology, Harare, Zimbabwe.

ORCID-Profile: Bianca Kruger, Delva Shamley, Nyarai Desiree Soko, Collet Dandara

Förderung

  • University of Cape Town
  • South African Medical Research Council (SAMRC)
  • Council for Scientific and Industrial Research (CSIR)
  • Human Resource Development Centre, Council of Scientific And Industrial Research

Zitieren

APA

Kruger, B., Shamley, D., Soko, N. D., & Dandara, C. (2024). Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data. Clinical and Translational Science. https://doi.org/10.1111/cts.13761

Vancouver

Kruger B, Shamley D, Soko ND, Dandara C. Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data. Clinical and Translational Science. 2024. doi:10.1111/cts.13761

BibTeX
@article{Kruger2024,
  author = {Kruger, Bianca and Shamley, Delva and Soko, Nyarai Desiree and Dandara, Collet},
  title = {Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13761}
}
Kostenlos starten →